AU2018309085B2 - Compounds for the prevention and treatment of medical disorders and uses thereof - Google Patents

Compounds for the prevention and treatment of medical disorders and uses thereof Download PDF

Info

Publication number
AU2018309085B2
AU2018309085B2 AU2018309085A AU2018309085A AU2018309085B2 AU 2018309085 B2 AU2018309085 B2 AU 2018309085B2 AU 2018309085 A AU2018309085 A AU 2018309085A AU 2018309085 A AU2018309085 A AU 2018309085A AU 2018309085 B2 AU2018309085 B2 AU 2018309085B2
Authority
AU
Australia
Prior art keywords
compound
gal
ags
compounds
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018309085A
Other languages
English (en)
Other versions
AU2018309085A1 (en
Inventor
Ryan George
Joseph M. Johnson
Raphael NIR
Sharon Shechter
Peter G. Traber
Eliezer Zomer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galectin Sciences LLC
Original Assignee
Galectin Sciences LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galectin Sciences LLC filed Critical Galectin Sciences LLC
Publication of AU2018309085A1 publication Critical patent/AU2018309085A1/en
Application granted granted Critical
Publication of AU2018309085B2 publication Critical patent/AU2018309085B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2018309085A 2017-08-03 2018-08-03 Compounds for the prevention and treatment of medical disorders and uses thereof Active AU2018309085B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762540860P 2017-08-03 2017-08-03
US62/540,860 2017-08-03
PCT/US2018/045175 WO2019028357A1 (en) 2017-08-03 2018-08-03 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF MEDICAL DISORDERS AND USES THEREOF

Publications (2)

Publication Number Publication Date
AU2018309085A1 AU2018309085A1 (en) 2020-02-06
AU2018309085B2 true AU2018309085B2 (en) 2022-12-08

Family

ID=65233534

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018309085A Active AU2018309085B2 (en) 2017-08-03 2018-08-03 Compounds for the prevention and treatment of medical disorders and uses thereof

Country Status (12)

Country Link
US (3) US11583530B2 (https=)
EP (1) EP3661502A4 (https=)
JP (1) JP7498108B2 (https=)
KR (1) KR102692840B1 (https=)
CN (1) CN111032039B (https=)
AU (1) AU2018309085B2 (https=)
BR (1) BR112020001698A2 (https=)
CA (1) CA3069745A1 (https=)
IL (1) IL272097B2 (https=)
MX (1) MX2020001256A (https=)
WO (1) WO2019028357A1 (https=)
ZA (1) ZA202000375B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
EP3661502A4 (en) 2017-08-03 2020-12-02 Galectin Sciences, LLC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF MEDICAL CONDITIONS AND THEIR USES
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
WO2022261113A2 (en) * 2021-06-08 2022-12-15 Truebinding, Inc. Anti-gal3 antibodies and methods of use for insulin resistance
CN113476442A (zh) * 2021-07-28 2021-10-08 上海交通大学医学院附属第九人民医院 化合物gb-0139在治疗心肌梗死后心肌过度纤维化的药物中的应用
GB2631509A (en) * 2023-07-04 2025-01-08 Univ Liverpool Compositions
GB2631507A (en) * 2023-07-04 2025-01-08 Univ Liverpool Compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158913A2 (en) * 2011-05-17 2012-11-22 Discoverybiomed Inc. Treating protein folding disorders with small molecule cftr correctors
CN106220631A (zh) * 2016-07-26 2016-12-14 中山大学 一种7位氟取代Isaindigotone衍生物及其制备方法和在制备抗癌药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT377586B (de) * 1981-06-30 1985-04-10 Erba Farmitalia Verfahren zur herstellung von substituierten pyrrolo-(2,1-b)-chinazolinen und pyrido(2,1-b)chinazolinen
ES8501397A1 (es) * 1982-08-05 1984-11-16 Erba Farmitalia "procedimiento para preparar derivados de quinazolina"
SE0100172D0 (sv) * 2001-01-22 2001-01-22 Ulf Nilsson New inhibitors against galectins
BR0206844A (pt) 2001-01-31 2005-07-12 Synaptic Pharma Corp Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos
US20030078271A1 (en) 2001-01-31 2003-04-24 Blackburn Thomas P. Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
ES2278197T3 (es) * 2002-07-09 2007-08-01 Actelion Pharmaceuticals Ltd. Derivados de 7,8,9,10-tetrahidro-6h-azepino, 6,7,8,9-tetrahidro-pirido y 2,3-dihidro-2h-pirrolo(1,2-b)-quinazolinona.
US7220775B2 (en) 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain
DE10304141B4 (de) * 2003-02-03 2006-03-09 Hf Arzneimittelforschung Gmbh Verfahren zur Herstellung von Chinazolin-Alkaloiden
RU2606635C2 (ru) * 2011-07-13 2017-01-10 Сантен Фармасьютикал Ко., Лтд. Новое соединение, проявляющее ингибиторную активность в отношении parp
WO2016004093A2 (en) 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
JP6904906B2 (ja) * 2015-01-30 2021-07-21 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤
CN105272986A (zh) * 2015-06-15 2016-01-27 厦门医学高等专科学校 一种可抑制乙酰胆碱酯酶活性的化合物或其制备方法和应用
EP3661502A4 (en) 2017-08-03 2020-12-02 Galectin Sciences, LLC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF MEDICAL CONDITIONS AND THEIR USES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158913A2 (en) * 2011-05-17 2012-11-22 Discoverybiomed Inc. Treating protein folding disorders with small molecule cftr correctors
CN106220631A (zh) * 2016-07-26 2016-12-14 中山大学 一种7位氟取代Isaindigotone衍生物及其制备方法和在制备抗癌药物中的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHARLOTTE SUTHERELL, STEVEN LEY: "On the Synthesis and Reactivity of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-ones", SYNTHESIS, GEORG THIEME VERLAG, STUTTGART, DE., vol. 49, no. 01, 19 December 2016 (2016-12-19), STUTTGART, DE. , pages 135 - 144, XP055741554, ISSN: 0039-7881, DOI: 10.1055/s-0035-1562792 *
VEENU MANGLA, KUNAL NEPALI, GAGANDIP SINGH, JAGJEET SINGH, SANTOSH GURU, MANISH GUPTA, PRIYA MAHAJAN, AJIT SAXENA, KANAYA DHAR: "Structure Activity Relationship of Arylidene Pyrrolo and Pyrido [2,1-b] Quinazolones as Cytotoxic Agents: Synthesis, SAR Studies, Biological Evaluation and Docking Studies", MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD., NL, vol. 9, no. 5, 1 June 2013 (2013-06-01), NL , pages 642 - 650, XP055741513, ISSN: 1573-4064, DOI: 10.2174/1573406411309050003 *
YU-QING WANG ET AL, JOURNAL OF MEDICINAL CHEMISTRY, (2017-07-17), vol. 60, no. 16, doi:10.1021/acs.jmedchem.7b00421, ISSN 0022-2623, pages 6924 6941 *

Also Published As

Publication number Publication date
EP3661502A4 (en) 2020-12-02
BR112020001698A2 (pt) 2020-07-21
CN111032039A (zh) 2020-04-17
KR20200035982A (ko) 2020-04-06
EP3661502A1 (en) 2020-06-10
JP2020529988A (ja) 2020-10-15
KR102692840B1 (ko) 2024-08-07
IL272097B1 (en) 2024-02-01
US20260060985A1 (en) 2026-03-05
AU2018309085A1 (en) 2020-02-06
CA3069745A1 (en) 2019-02-07
IL272097B2 (en) 2024-06-01
ZA202000375B (en) 2025-04-30
MX2020001256A (es) 2020-08-17
US20200147088A1 (en) 2020-05-14
JP7498108B2 (ja) 2024-06-11
IL272097A (en) 2020-03-31
US20230116370A1 (en) 2023-04-13
US11583530B2 (en) 2023-02-21
WO2019028357A1 (en) 2019-02-07
CN111032039B (zh) 2024-03-26
US12377102B2 (en) 2025-08-05

Similar Documents

Publication Publication Date Title
AU2018309085B2 (en) Compounds for the prevention and treatment of medical disorders and uses thereof
AU2018265571B2 (en) Compounds for the prevention and treatment of diseases and the use thereof
US10577366B2 (en) Crystalline forms of a compound that inhibits bromodomain
ES2755125T3 (es) Derivados de 2H-1,2,3-triazol como inhibidores de fibrosis
TWI433677B (zh) 雜環化合物及其用途
EP2925742B1 (en) Kinase inhibitors
KR20230044416A (ko) Parp 억제제로서의 인돌로 헵타밀 옥심 유사체 결정 및 그의 제조방법
AU2018265813A1 (en) Compounds for the treatment of systemic insulin resistance disorders and the use thereof
WO2019206069A1 (zh) 一种二芳基巨环化合物、药物组合物以及其用途
CN110143961A (zh) 一种基于vhl配体诱导bet降解的吡咯并吡啶酮类双功能分子化合物
US20210347775A1 (en) Deuterated Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer
TW200304817A (en) Chemical compounds
TW202016110A (zh) Ｊａｋ激酶家族之小分子抑制劑
CN105531274A (zh) 作为RORc调节剂的酮-咪唑并吡啶衍生物
CN113999235B (zh) 含氮杂环化合物的固体形式及其药物组合物和用途
CN111777626A (zh) 一类维奈妥拉与二氢青蒿素拼合物及其制备与应用
CN113773273B (zh) 苯并异噻唑类化合物及其制备方法和用途
HK40130017A (zh) 碳酸酐酶抑制剂及其使用方法
CN117820340A (zh) Atr抑制剂及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)